<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>AI Agents in Drug Discovery - Health AI Hub</title>
    <meta name="description" content="This paper presents a comprehensive overview of how AI agents, built upon large language models (LLMs) coupled with perception, computation, action, and memory ">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>AI Agents in Drug Discovery</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2510.27130v1" target="_blank">2510.27130v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-10-31
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Srijit Seal, Dinh Long Huynh, Moudather Chelbi, Sara Khosravi, Ankur Kumar, Mattson Thieme, Isaac Wilks, Mark Davies, Jessica Mustali, Yannick Sun, Nick Edwards, Daniil Boiko, Andrei Tyrin, Douglas W. Selinger, Ayaan Parikh, Rahul Vijayan, Shoman Kasbekar, Dylan Reid, Andreas Bender, Ola Spjuth
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.LG
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.95 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2510.27130v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="http://arxiv.org/pdf/2510.27130v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper presents a comprehensive overview of how AI agents, built upon large language models (LLMs) coupled with perception, computation, action, and memory tools, are transforming drug discovery by autonomously reasoning, acting, and learning through complex research workflows. It details various agentic AI architectures and illustrates their real-world applications across key stages of drug discovery, demonstrating substantial gains in speed, reproducibility, and scalability, compressing multi-month workflows into hours.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This research is profoundly relevant to medicine and health as it outlines how AI agents can drastically accelerate the drug discovery and development pipeline, potentially leading to faster identification of novel therapies, more efficient drug repurposing, and ultimately, quicker access to life-saving treatments for patients.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>AI agents are applied to automate and accelerate various stages of drug discovery, including literature synthesis, toxicity prediction, automated protocol generation, small-molecule synthesis, drug repurposing, and end-to-end decision-making. This directly supports the development of new treatments and medications for human diseases, enhancing speed, reproducibility, and scalability in a critical area of medical advancement.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>AI agents are conceptualized as autonomous systems leveraging LLMs alongside perception, computation, action, and memory tools to navigate complex biomedical research workflows.</li>
                    
                    <li>These agentic AI systems are capable of integrating diverse biomedical data, executing tasks, carrying out experiments via robotic platforms, and iteratively refining hypotheses in closed-loop systems.</li>
                    
                    <li>The paper provides a technical overview of agentic AI architectures, including ReAct, Reflection, Supervisor, and Swarm systems.</li>
                    
                    <li>Applications illustrated span critical stages of drug discovery: literature synthesis, toxicity prediction, automated protocol generation, small-molecule synthesis, drug repurposing, and end-to-end decision-making.</li>
                    
                    <li>This work is highlighted as the first comprehensive analysis of real-world implementations and quantifiable impacts of agentic AI systems deployed in operational drug discovery settings.</li>
                    
                    <li>Early implementations show substantial benefits, including compressing workflows that previously took months into hours, while significantly enhancing speed, reproducibility, and scalability, all with maintained scientific traceability.</li>
                    
                    <li>Current challenges include addressing data heterogeneity, ensuring system reliability, managing privacy concerns, and developing robust benchmarking methodologies for these advanced AI systems.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The paper provides a conceptual and technical overview of agentic AI architectures, analyzing their design principles and functionalities. It then illustrates their practical applications across various stages of drug discovery, synthesizing evidence from real-world implementations to assess their quantifiable impacts. This constitutes a comprehensive review and analysis of emerging AI technologies in a specific scientific domain.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>AI agents, by integrating LLMs with specialized tools, can autonomously perform intricate drug discovery tasks, significantly enhancing efficiency and scale. Real-world deployments demonstrate a transformative impact, reducing workflow durations from months to hours while maintaining scientific rigor and traceability, showcasing substantial gains in speed, reproducibility, and scalability.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>The advancements in AI-driven drug discovery could lead to a dramatic reduction in the time and cost associated with bringing new drugs to market. This would enable faster identification of drug candidates, accelerate validation, facilitate novel drug repurposing, and streamline experimental design, directly translating into quicker availability of effective and potentially personalized treatments for a wide range of diseases.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The current deployment of AI agents in drug discovery faces challenges including managing the heterogeneity of diverse biomedical datasets, ensuring the reliability and robustness of complex AI systems, addressing critical privacy concerns related to sensitive patient and research data, and establishing standardized benchmarking protocols to evaluate their performance effectively.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>Future efforts should concentrate on further developing these AI technologies to more profoundly support scientific discovery and accelerate the translation of AI-driven insights into practical applications, clinical interventions, and tangible patient benefits, ensuring a seamless bridge between technological advancement and medical progress.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Pharmacology</span>
                    
                    <span class="tag">Drug Development</span>
                    
                    <span class="tag">Toxicology</span>
                    
                    <span class="tag">Pharmaceutical Research</span>
                    
                    <span class="tag">Biomedical Informatics</span>
                    
                    <span class="tag">Precision Medicine</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">AI Agents</span>
                    
                    <span class="tag tag-keyword">Drug Discovery</span>
                    
                    <span class="tag tag-keyword">Large Language Models</span>
                    
                    <span class="tag tag-keyword">Autonomous Systems</span>
                    
                    <span class="tag tag-keyword">Drug Repurposing</span>
                    
                    <span class="tag tag-keyword">Robotic Platforms</span>
                    
                    <span class="tag tag-keyword">Pharmaceutical R&D</span>
                    
                    <span class="tag tag-keyword">AI Architectures</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Artificial intelligence (AI) agents are emerging as transformative tools in
drug discovery, with the ability to autonomously reason, act, and learn through
complicated research workflows. Building on large language models (LLMs)
coupled with perception, computation, action, and memory tools, these agentic
AI systems could integrate diverse biomedical data, execute tasks, carry out
experiments via robotic platforms, and iteratively refine hypotheses in closed
loops. We provide a conceptual and technical overview of agentic AI
architectures, ranging from ReAct and Reflection to Supervisor and Swarm
systems, and illustrate their applications across key stages of drug discovery,
including literature synthesis, toxicity prediction, automated protocol
generation, small-molecule synthesis, drug repurposing, and end-to-end
decision-making. To our knowledge, this represents the first comprehensive work
to present real-world implementations and quantifiable impacts of agentic AI
systems deployed in operational drug discovery settings. Early implementations
demonstrate substantial gains in speed, reproducibility, and scalability,
compressing workflows that once took months into hours while maintaining
scientific traceability. We discuss the current challenges related to data
heterogeneity, system reliability, privacy, and benchmarking, and outline
future directions towards technology in support of science and translation.</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>45 pages, 12 figures</p>
            </section>
            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>